COgnitioN With VERiciGuat Evaluation in Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT06601465
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT06601465
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT06601465. Randomized; no masking; primary purpose treatment. Start 2025-06-03 (actual); primary completion 2028-07-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- COgnitioN With VERiciGuat Evaluation in Heart Failure
- Acronym
- CONVERGE-HF
- Condition
- Heart Failure
- Condition
- Cognitive Impairment
- Intervention (Drug)
- Vericiguat
- Lead sponsor
- University of Alberta
- Collaborator
- Ottawa Heart Institute Research Corporation
- Collaborator
- Heart and Stroke Foundation of Canada
Record details
- Record id
cardio:ct-nct06601465- Content hash
9a023e147cd49bf48cb4859d6a5a2d7a2238b926385e1345a188eb6b0e94b18a